Craig Malzahn, Chief Technology Officer of REGENXBIO Inc., filed a Form 4 on November 3, 2026, disclosing the acquisition of 27,777 shares of common stock underlying a time-based restricted stock unit award dated November 1, 2026.

Key Highlights

  • Reporting person: Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (NASDAQ:RGNX)
  • Transaction date: November 1, 2026, with 27,777 shares acquired at a price of $0.00
  • Transaction code: A (acquisition), recorded in Table I as Non-Derivative Securities
  • Vesting schedule: 1/3 of the RSU shares vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, subject to continuous service to the issuer
  • Beneficial ownership following transaction: 109,737 shares of common stock held directly

REGENXBIO CTO Craig Malzahn Discloses RSU Award and Updated Share Position

According to the filing, Craig Malzahn, serving as Chief Technology Officer of REGENXBIO Inc., reported the acquisition of 27,777 shares of common stock underlying a time-based restricted stock unit award. The transaction was recorded with a transaction date of November 1, 2026, and a price of $0.00, consistent with an RSU grant rather than an open-market purchase. The filing was signed by Patrick J. Christmas as attorney-in-fact on November 3, 2026.

The filing's explanation of responses states that the award represents shares of common stock underlying a time-based RSU, with "1/3rd of the shares subject to the RSU award shall vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, while the recipient provides continuous service to the Issuer." No derivative securities transactions were reported in Table II of the filing.

Following the reported transaction, Malzahn's direct beneficial ownership of REGENXBIO common stock stands at 109,737 shares, as disclosed in the filing. The form was filed by one reporting person and indicates Malzahn holds the shares directly. No indirect ownership or amendment to a prior filing was noted.

What Was Disclosed

Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (NASDAQ:RGNX), disclosed the acquisition of a 27,777-share RSU award on November 1, 2026, vesting in equal thirds over three years, bringing his total direct beneficial ownership to 109,737 shares.